Interest in minimally invasive surgery has increased in recent decades. Roboticassisted laparoscopic surgery (RALS) was introduced as the latest advance in minimally invasive surgery. RALS has the potential to provide better clinical outcomes in rectal cancer surgery, allowing for precise dissection in the narrow pelvic space. In addition, RALS represents an important advancement in surgical education with respect to use of the dual-console robotic surgery system. Because the public health insurance systems in Japan have covered the cost of RALS for rectal cancer since April 2018, RALS has been attracting increasingly more attention. Although no overall robust evidence has yet shown that RALS is superior to laparoscopic or open surgery, the current evidence supports the notion that technically demanding subgroups (patients with obesity, male patients, and patients treated by extended procedures) may benefit from RALS. Technological innovation is a constantly evolving field. Several companies have been developing new robotic systems that incorporate new technology. This competition among companies in the development of such systems is anticipated to lead to further improvements in patient outcomes as well as drive down the cost of RALS, which is one main concern of this new technique. Robotic-assisted laparoscopic surgery (RALS) was introduced as the latest advancement in minimally invasive surgery to overcome
some of the disadvantages of conventional laparoscopic surgery (CLS). The advantages of robotic assistance include providing an immersive three-dimensional view, better ergonomics and enhanced dexterity with tremor filtration and motion scaling, instrument articulation, and a stable endoscope platform. Due to these advantages, RALS has the potential to provide better clinical, oncological, and functional outcomes in rectal cancer surgery and allow for precise dissection in the narrow pelvic space. In this review article, we state an overview of the history, current evidence from clinical studies, and future perspective of RALS for rectal cancer.
| RALS: A NOVEL FRONTIER IN MINIMALLY INVASIVE SURGERY FOR RECTAL CANCER
The most commonly used system for robotic surgery is the da Vinci in Asia. 9 Several new robotic systems have focused on improving current systems and incorporating new technology. The Telelap ALF-X by TransEnterix (Morrisville, NC, USA) provides direct force feedback that allows the surgeons to sense the applied force to the organ. 10 The Flex Robotic System by Medrobotics (Raynham, MA, USA) is intended for transluminal surgery and obtained FDA approval in 2018. 11 The SPORT Surgical System by Titan Medical (Toronto, Canada) has been developed for single-port access robotic surgery.
In the field of colorectal surgery, Weber et al. 12 performed the first robotic-assisted colectomy for benign disease in 2001, and Pigazzi et al. 13 reported the first robotic-assisted total mesorectal excision (TME) in 2006. The number of robotic colorectal procedures performed globally has rapidly increased. Because the public health insurance system in Japan has covered the cost of RALS for rectal cancer since April 2018, robotic-assisted rectal surgery has been attracting increasingly more attention. 35 reported no significant difference in the operative times, conversion to laparotomy, estimated blood loss, or length of stay between patients with visceral obesity and non-obese patients treated by RALS, whereas the operative time, estimated blood loss, and length of hospital stay were significantly worse in the patients with visceral obesity treated by CLS. RALS and its advantages in dexterity, visualization, and surgeon ergonomics may help to overcome the challenges of CLS in obese patients.
| SHORT-TE RM OUTCOMES

| Intraoperative outcomes
| LONG-TERM OUTCOMES
Only a few studies have reported on long-term outcomes because of the comparatively short history of RALS for rectal cancer. RALS was compared with CLS in four studies and with OS in two studies. 23, 24, [36] [37] [38] [39] Kim et al. reported that RALS was a good prognostic factor compared with CLS in terms of overall survival and cancerspecific survival. The potential benefits with respect to long-term outcomes will be addressed in phase 3 prospective RCTs currently in progress, such as the ROLARR trial and the comparison of laparoscopic vs robot-assisted for rectal cancer (COLRAR trial).
| UROGENITAL FUNCTION
In the current treatment of rectal cancer, surgeons focus on pre- preserving urinary and sexual function after TME. 40 They concluded that the benefits of RALS were probably due to the superior movements of the wristed instruments as well as the 
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Odds ratio 1.00 N.S. No difference CLS, conventional laparoscopic surgery; N.S., not significant; RALS, robotic-assisted laparoscopic surgery; RCT, randomized control trial.
high-quality three-dimensional vision, both of which were helpful for identification and precise preservation of the neural component. Recent large cohort studies have shown that the rate of urinary retention after rectal cancer surgery is significantly lower in RALS than CLS. 22, 23, 28 Several studies have assessed urinary and sexual function after RALS and CLS using the International Prostate Symptom Score (IPSS) and the International Index of Erectile Function questionnaire (Table 2 ).
14, [41] [42] [43] [44] [45] Some of these studies showed significantly improved urinary continence at 3, 6, and 12 months after TME performed by RALS. In addition, most of them showed that RALS conferred significantly improved sexual function at 3, 6, and 12 months after TME compared with CLS. Kim et al. noted that markedly impaired urinary function was only found in male patients in both the RALS and CLS groups. 43 A significant difference in the IPSS between the RALS and CLS groups was only found in male patients at 6 months after TME. These results may indicate that preservation of pelvic autonomic nerves is more difficult in male patients because of their narrower and deeper pelvis. Male patients may benefit more from robotic surgery than female patients. Further large prospective studies with long-term follow-up are needed. [55] [56] [57] [58] [59] These results suggest that the learning curve for RALS may be shorter than that of CLS for rectal cancer. postoperative complications when using a dual-console system than a single-console system. 60 Although studies evaluating dualconsole robotic training systems are insufficient to date, they have the potential to change surgical training strategies in the near future.
| LEARNING CURVE
| COSTS
One main disadvantage of RALS is the high cost of initial attainment and subsequent maintenance of the robotic system. Decreasing these costs for the widespread adoption of RALS is in demand. One study showed that increased proficiency in RALS shortens the operative time and lowers the overall costs. 61 Overall costs are also affected by the length of hospital stay, postoperative complication rates, and readmission rates. Hottenrott stated that the cost can be reduced by the accumulation of robotic cases in specialized centers as well as competition for machines or related instruments among companies. 62 To reduce the per-patient costs of RALS, hospitals need to raise the number of RALS; this can be accomplished by raising the number of surgeons. Moreover, several companies are trying to develop new robotic surgical systems, and this new competition will reduce the cost of RALS and lead to innovations of technology.
With these improvements in clinical outcomes, the increasing expertise of surgeons in RALS, and the sustained efforts to reduce the costs of the robotic surgical system (attainment and maintenance costs), RALS may become the most cost-effective approach for rectal cancer.
| EXTEN DED PROCEDURES
| Lateral lymph node dissection
Advanced lower rectal cancer metastasizes to the lateral lymph nodes of the pelvic wall with an incidence of 15.6%-20.1%. 63, 64 A large multicenter RCT from Japan showed inferiority of mesorectal excision alone to mesorectal excision with lateral lymph node dissection (LLND). In that study, LLND reduced the incidence of local recurrence by 50% compared with mesorectal excision alone in patients with stage II and III rectal cancer. 65 According to the current Japanese guidelines, LLND is recommended for T3 and T4 tumors located distal to the peritoneal reflection. 64 feasible; the conversion rate to OS was 0.0% and 2.8%, respectively, and the median blood loss was 41 and 200 mL, respectively. Both studies showed that the rate of CRM involvement was 0%.
| CONCLUSION AND FUTURE
PE RSPECTIVE
Robotic-assisted rectal surgery provides several advantages over CLS by advanced technologies including articulating instruments and motion scaling, especially when performing an operation in the narrow pelvic space. Current evidence shows the robotic approach has been proven technically and oncologically safe and feasible for rectal cancer. Robotic systems also have great advantages in terms of surgical education using a dual console.
Although the initial results are promising, no overall robust evidence that RALS is superior to CLS or OS has yet been established. 
